Literature DB >> 15325838

Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.

James C Hogg1.   

Abstract

The airflow limitation that defines chronic obstructive pulmonary disease (COPD) is the result of a prolonged time constant for lung emptying, caused by increased resistance of the small conducting airways and increased compliance of the lung as a result of emphysematous destruction. These lesions are associated with a chronic innate and adaptive inflammatory immune response of the host to a lifetime exposure to inhaled toxic gases and particles. Processes contributing to obstruction in the small conducting airways include disruption of the epithelial barrier, interference with mucociliary clearance apparatus that results in accumulation of inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by inflammatory cells, and deposition of connective tissue in the airway wall. This remodelling and repair thickens the airway walls, reduces lumen calibre, and restricts the normal increase in calibre produced by lung inflation. Emphysematous lung destruction is associated with an infiltration of the same type of inflammatory cells found in the airways. The centrilobular pattern of emphysematous destruction is most closely associated with cigarette smoking, and although it is initially focused on respiratory bronchioles, separate lesions coalesce to destroy large volumes of lung tissue. The panacinar pattern of emphysema is characterised by a more even involvement of the acinus and is associated with alpha1 antitrypsin deficiency. The technology needed to diagnose and quantitate the individual small airway and emphysema phenotypes present in people with COPD is being developed, and should prove helpful in the assessment of therapeutic interventions designed to modify the progress of either phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15325838     DOI: 10.1016/S0140-6736(04)16900-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  334 in total

1.  Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease.

Authors:  Vasiliy V Polosukhin; Justin M Cates; William E Lawson; Rinat Zaynagetdinov; Aaron P Milstone; Pierre P Massion; Sebahat Ocak; Lorraine B Ware; Jae Woo Lee; Russell P Bowler; Alexey V Kononov; Scott H Randell; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  Preclinical vascular disease identifies smokers at risk for COPD.

Authors:  James D Crapo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-04       Impact factor: 11.205

3.  Recovery of Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction after Smoking Cessation.

Authors:  Clifford A Courville; S Vamsee Raju; Bo Liu; Frank J Accurso; Mark T Dransfield; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

4.  Effects of atorvastatin on smoking-induced alveolar injury in rat lungs.

Authors:  Tekin Yildiz; M Serhan Tasdemir; Selcuk Tunik; Gungor Ates; Selahaddin Tekes; Iskender Kaplanoglu; Fusun Topcu; Murat Akkus
Journal:  Curr Ther Res Clin Exp       Date:  2009-10

5.  A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis.

Authors:  Emma L Beckett; Richard L Stevens; Andrew G Jarnicki; Richard Y Kim; Irwan Hanish; Nicole G Hansbro; Andrew Deane; Simon Keely; Jay C Horvat; Ming Yang; Brian G Oliver; Nico van Rooijen; Mark D Inman; Roberto Adachi; Roy J Soberman; Sahar Hamadi; Peter A Wark; Paul S Foster; Philip M Hansbro
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

6.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Authors:  Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

7.  Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease.

Authors:  Hironi Makita; Yasuyuki Nasuhara; Katsura Nagai; Yoko Ito; Masaru Hasegawa; Tomoko Betsuyaku; Yuya Onodera; Nobuyuki Hizawa; Masaharu Nishimura
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

Review 8.  The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research.

Authors:  Jeffrey L Curtis; Christine M Freeman; James C Hogg
Journal:  Proc Am Thorac Soc       Date:  2007-10-01

9.  The Association Between Bone Mineral Density and Airflow Limitation in a Cohort of Fit Elderly Women.

Authors:  Caterina Trevisan; A Vianello; N Veronese; S Carraro; S Pizzato; P Lucato; G Girotti; C Rinaldo; A Coin; E Manzato; G Sergi
Journal:  Lung       Date:  2016-10-03       Impact factor: 2.584

10.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.